Literature DB >> 2280235

Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man.

B Ullman1, A Franco-Cereceda, J Hulting, J M Lundberg, A Sollevi.   

Abstract

Plasma levels of neuropeptide Y-like immunoreactivity (NPY-LI) and noradrenaline were studied for 25 h in 22 patients with acute ischaemic heart disease. On admission, NPY-LI levels were above normal in 16 patients, and 20 patients had increased noradrenaline levels. The initial plasma NPY-LI did not differ between patients with acute myocardial infarction (AMI) and angina pectoris. Initial plasma noradrenaline levels were higher in patients with AMI than in those with angina pectoris. Plasma levels of noradrenaline remained elevated in AMI patients, but decreased towards normal values in patients with angina pectoris. Levels of NPY-LI returned to normal within 25 h in all patients. Tachycardia and left ventricular failure were related to high NPY-LI and noradrenaline levels. A positive correlation was found between noradrenaline and NPY-LI in plasma. It is suggested that neuropeptide Y (NPY), an endogenous vasoconstrictor peptide, should be considered as one of the mediators involved in the cardiovascular response to sympathetic activation induced by myocardial ischaemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280235     DOI: 10.1111/j.1365-2796.1990.tb00283.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Changes in plasma catecholamine and neuropeptide Y levels after sympathetic activation in dogs.

Authors:  M F Poncet; C Damase-Michel; G Tavernier; M A Tran; M Berlan; J L Montastruc; P Montastruc
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 2.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

3.  Is neuropeptide Y co-released with catecholamines in experimental arterial hypertension following sinoaortic denervation?

Authors:  G Tavernier; C Damase-Michel; G Portolan; M A Tran; J L Montastruc
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

4.  Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.

Authors:  Eckhard Schwertfeger; Thomas Klein; Oliver Vonend; Vitus Oberhauser; Johannes Stegbauer; Lars Christian Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-22       Impact factor: 3.000

5.  Levels of plasma neuropeptide Y and other vasoactive substances during head-up tilt in normal and essential hypertensive subjects.

Authors:  F Veglio; D Schiavone; G Mengozzi; P Molino; L Chiandussi
Journal:  Clin Auton Res       Date:  1995-04       Impact factor: 4.435

Review 6.  Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review.

Authors:  Yan Zhang; Chu-Yun Liu; Wei-Can Chen; Yan-Chuan Shi; Cong-Mei Wang; Shu Lin; He-Fan He
Journal:  Cell Biosci       Date:  2021-08-03       Impact factor: 7.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.